OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma

Introduction

8 patients were infused with fresh (non-cryopreserved) OBX-115, had 21 dose of ACZ, and 12-weeks of follow-up (Figure 2)

Objective responses were observed in 3 of 6 patients (50%; ORR Table 4)

All patients experienced disease control

All patients were alive at the time of the data cut-off

Methods

Patient disposition (Table 3)

Table 1. Baseline Patient and Disease Characteristics (N=6)

Table 2. Treatment Characteristics (N=6)

Table 3. Safety (N=6)

Table 4. Efficacy (RECIST v1.1 [N=6])

Results

Primary endpoints were met

Table 2: Treatment Characteristics (N=6)

Table 3: Safety (N=6)